Skip to Content

Join the 'Metformin' group to help and get support from people like you.

Metformin News

Native Americans Make Progress Against Diabetes Complication

Posted 10 days ago by Drugs.com

TUESDAY, Jan. 10, 2017 – Diabetes-related kidney failure among Native American adults fell by more than half over almost 20 years, a U.S. Centers for Disease Control and Prevention report shows. The change is due to improvements in diabetes and kidney care, according to the report. The new research also found that among these patients, blood sugar control improved 10 percent between 1996 and 2014, and the use of medicine to protect kidneys rose from 42 percent to 74 percent over 5 years. Average blood pressure in Native Americans with diabetes and high blood pressure was well controlled (133/76 in 2015), the findings showed. In addition, more than 60 percent of Native Americans aged 65 and older with diabetes had a urine test for kidney damage in 2015, compared with 40 percent of Medicare patients with diabetes in 2013, the researchers said. "The Indian Health Service (IHS) has made ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Renal Failure, Glucophage, Novolog, Glipizide, Humalog, Insulin Resistance, Janumet, Glyburide, Lantus Solostar, Levemir, Glimepiride, Pre-Diabetes, Chronic Kidney Disease, Novolin R, Amaryl, Novolin N

Metformin Still Best Choice for First Type 2 Diabetes Treatment

Posted 18 days ago by Drugs.com

MONDAY, Jan. 2, 2017 – Newly updated guidelines reaffirm that metformin is the first-line drug for people with type 2 diabetes, and that several other medications – including newer ones – can be added if needed. The recommendations come from the American College of Physicians (ACP). The American Academy of Family Physicians endorsed the new guidelines. The ACP updated the guidelines because of new research into diabetes drugs, and the U.S. Food and Drug Administration approval of new diabetes drugs. "Metformin, unless contraindicated, is an effective treatment strategy because it has better effectiveness, is associated with fewer adverse effects, and is cheaper than most other oral medications," ACP president Dr. Nitin Damle said in a college news release. "The escalating rates of obesity in the U.S. are increasing the incidence and prevalence of diabetes substantially. Metformin has ... Read more

Related support groups: Diabetes, Type 2, Metformin, Januvia, Glucophage, Glipizide, Janumet, Glyburide, Invokana, Actos, Glimepiride, Pre-Diabetes, Amaryl, Tradjenta, Pioglitazone, Avandia, Glucophage XR, GlipiZIDE XL, Glucotrol, Farxiga, Jardiance

FDA Approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) for Adults with Type 2 Diabetes

Posted 13 Dec 2016 by Drugs.com

RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ – The U.S. Food and Drug Administration (FDA) has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used along with diet and exercise, Synjardy XR is indicated to improve blood sugar in adults with type 2 diabetes when both empagliflozin and metformin can be taken. It is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY). Synjardy XR is a combination of empagliflozin and metformin - two medicines with complementary mechanisms of action - to help improve blood glucose in adults with type 2 diabetes. Empagliflozin, a sodium-glucose co-transporter 2 inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Synjardy XR is the fourth FDA-approved treatment that contains empagliflozin. ... Read more

Related support groups: Diabetes, Type 2, Metformin, Synjardy, Empagliflozin, Empagliflozin/metformin

FDA Approves Invokamet XR (Canagliflozin/Metformin Hydrochloride Extended-Release) for the Treatment of Adults with Type 2 Diabetes

Posted 22 Sep 2016 by Drugs.com

RARITAN, N.J., September 21, 2016 – Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet XR - a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)—for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes when treatment with the two medications is appropriate.[1] Invokamet XR combines Invokana (canagliflozin), the most prescribed sodium glucose co-transporter 2 (SGLT2) inhibitor, with more than 9 million U.S. prescriptions since launch,[2] and an XR formulation of metformin. Metformin is commonly prescribed as an initial therapy for the treatment of type 2 diabetes. “Invokamet XR offers the convenience of once-daily dosing and provides physicians needed flexibility for tailoring treatment to the needs ... Read more

Related support groups: Diabetes, Type 2, Metformin, Invokana, Canagliflozin, Invokamet, Canagliflozin/metformin

Intensive Type 2 Diabetes Treatment Can Extend Survival: Study

Posted 8 Sep 2016 by Drugs.com

WEDNESDAY, Sept. 7, 2016 – Intensive management of type 2 diabetes can make a difference in how long and how well you live, even if you don't start until middle age, researchers report. People who were already at risk of type 2 diabetes complications were randomly selected to continue with their normal treatment or to be placed in an aggressive and multipronged treatment group. Two decades after the study began, the researchers found that people in the aggressive treatment group lived almost eight years longer. Not only that, they lived better – their risk of heart disease, kidney disease and blindness all dropped. The only complication that didn't seem to improve was nerve damage caused by diabetes. "Early, intensified intervention in type 2 diabetes patients with microalbuminuria with both target-driven pharmacological (medication) and behavioral actions increased life span. And, ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Victoza, Lantus, Januvia, Glucophage, Novolog, Glipizide, Humalog, Janumet, Saxenda, Byetta, Glyburide, Bydureon, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride

Older Drug May Help Type 1 Diabetics' Heart Health

Posted 6 Sep 2016 by Drugs.com

TUESDAY, Sept. 6, 2016 – An inexpensive medication normally given to people with type 2 diabetes may help preserve heart health in people with the less common form of diabetes – type 1, a small new study finds. Metformin is the standard first-line treatment for type 2 diabetes to help bring blood sugar levels down. It also appears to help repair damaged blood cells by increasing the number of blood vessel (vascular) stem cells, researchers said. "We have shown – both in test tube and in patients – the mechanism behind the cardioprotective effects of metformin," said the study's senior author, Dr. Jolanta Weaver. She's a senior lecturer in diabetes medicine at Newcastle University in England. "This is likely to lead to the development of new drugs for heart disease in diabetes," she added. Sanjoy Duttais is assistant vice president of translational development at JDRF, a nonprofit ... Read more

Related support groups: Metformin, Diabetes, Type 1, Glucophage, Janumet, Prevention of Cardiovascular Disease, Glucophage XR, Cardiovascular Risk Reduction, ActoPlus Met, Glumetza, Janumet XR, Glyburide/Metformin, Avandamet, Jentadueto, Glucovance, Metformin/Pioglitazone, Xigduo XR, Riomet, Fortamet, Kombiglyze XR, Synjardy

Diabetes Drug May Help Kids With Autism Fight Unwanted Pounds

Posted 24 Aug 2016 by Drugs.com

WEDNESDAY, Aug. 24, 2016 – The diabetes drug metformin may help overweight children and teens with autism slim down, a new study suggests. The study included 60 people with autism, aged 6 to 17. The patients were overweight due to the side effects of taking antipsychotic medications for irritability and agitation. For the study, participants were given either metformin or an inactive placebo for 16 weeks. Those given metformin had much greater reductions in body mass index (BMI) than those who took the placebo, the findings showed. BMI is an estimate of body fat based on weight and height. "Our results showed that [gastrointestinal] side effects occurred for more days in the metformin group compared to placebo group, but the large majority of children taking metformin were able to maintain their treatment. Importantly, the metformin didn't cause behavioral changes, such as increased ... Read more

Related support groups: Obesity, Metformin, Weight Loss, Glucophage, Autism, Janumet, Asperger Syndrome, Glucophage XR, ActoPlus Met, Glumetza, Glyburide/Metformin, Janumet XR, Jentadueto, Avandamet, Glucovance, Metformin/Pioglitazone, Riomet, Kombiglyze XR, Xigduo XR, Fortamet

FDA Expands Indication For Type 2 Diabetes Treatment Synjardy (Empagliflozin/Metformin Hydrochloride) To Include Treatment-Naïve Adults

Posted 22 Jul 2016 by Drugs.com

RIDGEFIELD, Conn., and INDIANAPOLIS, July 19, 2016 /PRNewswire/ – The U.S. Food and Drug Administration has approved an expanded indication for Synjardy (empagliflozin and metformin hydrochloride) tablets to include treatment-naïve adults with type 2 diabetes (T2D). Synjardy, from Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), is indicated as an adjunct to diet and exercise to improve glycemic control in adults with T2D when treatment with both empagliflozin and metformin is appropriate. Synjardy is a combination of empagliflozin (Jardiance) and metformin — two medicines with complementary mechanisms of action — to help control blood glucose in adults with T2D. Empagliflozin, a sodium glucose co-transporter-2 inhibitor, removes excess glucose through the urine by blocking glucose re-absorption in the kidney. Metformin, a commonly prescribed initial treatment for T2D, lowe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Synjardy, Empagliflozin, Empagliflozin/metformin

Which Diabetes Drug Is Best?

Posted 19 Jul 2016 by Drugs.com

TUESDAY, July 19, 2016 – No single drug to treat type 2 diabetes stands out from the pack when it comes to reducing the risks of heart disease, stroke or premature death, a new research review finds. The analysis of hundreds of clinical trials found no evidence that any one diabetes drug, or drug combination, beats out the others. Researchers said the results bolster current recommendations to first try an older, cheaper drug – metformin (Glumetza, Glucophage) – for most patients with type 2 diabetes. "There are very few things experts agree on, but this is one of them," said Dr. Kevin Pantalone, a diabetes specialist at the Cleveland Clinic and a member of the Endocrine Society. "Metformin, in the absence of contraindications or intolerability, should be the first-line agent to treat patients with type 2 diabetes," he said. Metformin can cause upset stomach and diarrhea, so some ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Janumet, Prevention of Cardiovascular Disease, Glucophage XR, Cardiovascular Risk Reduction, ActoPlus Met, Glumetza, Janumet XR, Glyburide/Metformin, Avandamet, Jentadueto, Glucovance, Metformin/Pioglitazone, Xigduo XR, Riomet, Fortamet, Kombiglyze XR, Synjardy

FDA Approves Once-Daily Jentadueto XR (linagliptin and metformin hydrochloride extended-release) for Type 2 Diabetes

Posted 11 Jun 2016 by Drugs.com

Ridgefield, Conn., and Indianapolis, May 31, 2016 – The U.S. Food and Drug Administration (FDA) has approved Jentadueto XR (linagliptin and metformin hydrochloride extended-release) tablets for the treatment of type 2 diabetes (T2D) in adults. Jentadueto XR, which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), is the seventh new treatment from the Boehringer Ingelheim-Lilly Diabetes alliance to be approved by the FDA in the last five years. Jentadueto XR combines 2.5 mg or 5 mg of linagliptin with 1000 mg of metformin. Linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, works by increasing hormones that stimulate the pancreas to produce more insulin and the liver to produce less glucose. Metformin, a commonly prescribed initial treatment for T2D, lowers glucose production by the liver and its absorption in the intestine. “Adults with type 2 diabetes are ... Read more

Related support groups: Diabetes, Type 2, Metformin, Diabetes Mellitus, Jentadueto, Linagliptin, Linagliptin/metformin

Intensive Blood Sugar Control May Be Too Much for Some With Type 2 Diabetes

Posted 6 Jun 2016 by Drugs.com

MONDAY, June 6, 2016 – Intensive treatment of blood sugar levels in some people with type 2 diabetes may cause serious complications, new research suggests. "In this study, we found that, particularly among older patients and patients with serious chronic conditions, intensive treatment nearly doubled the risk of severe hypoglycemia requiring medical attention, including hospitalization," said lead author Dr. Rozalina McCoy. She is an endocrinologist at the Mayo Clinic in Rochester, Minn. Hypoglycemia (low blood sugar) is a serious potential complication of diabetes treatment. The researchers said it can worsen quality of life and has been linked with cardiovascular events, dementia and death. The researchers reviewed information from more than 31,500 American adults. All had stable and controlled type 2 diabetes. None was taking insulin. None had a prior history of severe ... Read more

Related support groups: Diabetes, Type 2, Metformin, Insulin, Lantus, Dementia, Glucophage, Novolog, Glipizide, Humalog, Hypoglycemia, Janumet, Glyburide, Lantus Solostar, Invokana, Levemir, Actos, Glimepiride, Novolin R, Amaryl, Novolin N

FDA Expands Indication of Invokamet (canagliflozin/metformin HCl) to Include First-Line Treatment of Type 2 Diabetes

Posted 31 May 2016 by Drugs.com

RARITAN, N.J., May 24, 2016 – Janssen Pharmaceuticals, Inc. (Janssen), today announced the U.S. Food and Drug Administration (FDA) has approved Invokamet, a fixed-dose combination therapy of INVOKANA® (canagliflozin) and metformin hydrochloride, for first-line treatment of adults with type 2 diabetes. With this new approval, Invokamet may now be prescribed in adults with type 2 diabetes who are not already being treated with canagliflozin or metformin and may benefit from dual therapy.[1] Invokamet, the first combination of a sodium glucose co–transporter 2 (SGLT2) inhibitor and metformin available in the United States, was previously approved by the FDA in August 2014 as an adjunct to diet and exercise to improve blood glucose control in adults with type 2 diabetes not adequately controlled by either canagliflozin or metformin, or who are already being treated with both medications sep ... Read more

Related support groups: Diabetes, Type 2, Metformin, Canagliflozin, Invokamet, Canagliflozin/metformin

Coffee, Wine Good for Healthy Gut, Sodas May Be Bad

Posted 28 Apr 2016 by Drugs.com

THURSDAY, April 28, 2016 – The food you eat and the medicines you take can alter your gut bacteria in ways that either help or harm your health, two new studies suggest. Foods like fruits, vegetables, coffee, tea, wine, yogurt and buttermilk can increase the diversity of bacteria in a person's intestines. And that diversity can help ward off illness, said Dr. Jingyuan Fu, senior author of one of the studies. "It is believed that higher diversity and richness [in gut bacteria] is beneficial," explained Fu. She is an associate professor of genetics at the University of Groningen in the Netherlands. On the other hand, foods containing loads of simple carbohydrates appear to reduce bacterial diversity in the gut, Fu and colleagues found. These include high-fat whole milk and sugar-sweetened soda. In addition, medications can also play a part in the makeup of your gut bacteria. Antibiotics, ... Read more

Related support groups: Metformin, Smoking, Heart Attack, Smoking Cessation, Caffeine, Glucophage, Fioricet, Excedrin, Janumet, Alert, Myocardial Infarction, Gastroenteritis, Fiorinal, Excedrin Migraine, Cafergot, Glucophage XR, Fiorinal with Codeine, Norgesic, Esgic, Fioricet with Codeine

Metformin Safer for Heart Than Other Common Type 2 Diabetes Drugs: Study

Posted 18 Apr 2016 by Drugs.com

MONDAY, April 18, 2016 – Metformin, the most frequently prescribed standalone drug for type 2 diabetes, is better for the heart than its closest competitors, a large analysis suggests. Metformin reduced the risk of dying from heart attack and stroke by about 30 percent to 40 percent compared with other commonly used drugs called sulfonylureas, such as glibenclamide, glimepiride, glipizide and tolbutamide, researchers report. "Pharmaceutical companies continue to make new drugs to reduce blood sugar and improve on safety concerns of the older drugs," said senior study author Dr. Shari Bolen. But, "while adults with diabetes often need more than one medication to control blood sugar, the newer medications do not appear to be safer than the older drugs," added Bolen. Metformin is still the safest and most effective type 2 diabetes medication, said Bolen. She is an assistant professor of ... Read more

Related support groups: Diabetes, Type 2, Metformin, Glucophage, Glipizide, Janumet, Glimepiride, Amaryl, Prevention of Cardiovascular Disease, Glucophage XR, GlipiZIDE XL, Cardiovascular Risk Reduction, Glucotrol, ActoPlus Met, Glucotrol XL, Glumetza, Glyburide/Metformin, Janumet XR, Avandamet, Jentadueto, Glucovance

Widely Used Type 2 Diabetes Drug May Reduce Cancer Death Risk

Posted 15 Apr 2016 by Drugs.com

FRIDAY, April 15, 2016 – Metformin, a commonly prescribed diabetes drug, may reduce the risk of dying from some cancers for postmenopausal women with type 2 diabetes, a new study suggests. The study found that for women with type 2 diabetes and cancer, the odds of dying from cancer appeared to be 45 percent higher compared to women with cancer who didn't have diabetes. But, in women with cancer who took metformin to treat their type 2 diabetes, the risk of dying from cancer seemed about the same as it was for women without diabetes. "Our findings from this large study may provide more evidence that postmenopausal women with diabetes and cancer may benefit from metformin therapy compared to other anti-diabetes therapy," said lead researcher Zhihong Gong. She's an assistant professor of oncology at the Roswell Park Cancer Institute, in Buffalo, N.Y. Gong cautioned, however, that this ... Read more

Related support groups: Diabetes, Type 2, Cancer, Metformin, Glucophage, Janumet, Glucophage XR, ActoPlus Met, Breast Cancer, Prevention, Glumetza, Janumet XR, Glyburide/Metformin, Avandamet, Jentadueto, Glucovance, Metformin/Pioglitazone, Xigduo XR, Riomet, Fortamet, Kombiglyze XR, Synjardy

Page 1 2 3 4 5 6 Next

Ask a Question

Further Information

Related Condition Support Groups

Diabetes, Type 2, Polycystic Ovary Syndrome, Insulin Resistance, Female Infertility

Related Drug Support Groups

Glucophage, Glucophage XR, Glumetza, Riomet, Fortamet

Metformin Patient Information at Drugs.com